Idioma:

Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA

Szczepanek, Joanna ; Skorupa, Monika ; Jarkiewicz-Tretyn, Joanna ; Cybulski, Cezary ; Tretyn, Andrzej

International journal of molecular sciences, 2023-04, Vol.24 (8), p.7235 [Periódico revisado por pares]

Switzerland: MDPI AG

Texto completo disponível

Citações Citado por

Enviar para

Título:
Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA
Autor: Szczepanek, Joanna ; Skorupa, Monika ; Jarkiewicz-Tretyn, Joanna ; Cybulski, Cezary ; Tretyn, Andrzej
Assuntos: antagomiRs ; Antagomirs - metabolism ; biomarkers ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - pathology ; Cancer ; Care and treatment ; chemoresistance ; Development and progression ; DNA ; DNA - metabolism ; DNA Methylation ; DNA methyltransferase inhibitors (DNMTi) ; Drug therapy, Combination ; Enzymes ; Epigenesis, Genetic ; Epigenetic inheritance ; epigenetic targets ; Female ; Gene expression ; Genes ; Genetic aspects ; Health aspects ; Histone Code ; histone deacetylase inhibitors (HDACi) ; Histone Deacetylase Inhibitors - pharmacology ; Histone Deacetylase Inhibitors - therapeutic use ; Humans ; Methylation ; Methyltransferases - metabolism ; MicroRNA ; MicroRNAs - metabolism ; Review ; Vorinostat
É parte de: International journal of molecular sciences, 2023-04, Vol.24 (8), p.7235
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Breast cancer exhibits various epigenetic abnormalities that regulate gene expression and contribute to tumor characteristics. Epigenetic alterations play a significant role in cancer development and progression, and epigenetic-targeting drugs such as DNA methyltransferase inhibitors, histone-modifying enzymes, and mRNA regulators (such as miRNA mimics and antagomiRs) can reverse these alterations. Therefore, these epigenetic-targeting drugs are promising candidates for cancer treatment. However, there is currently no effective epi-drug monotherapy for breast cancer. Combining epigenetic drugs with conventional therapies has yielded positive outcomes and may be a promising strategy for breast cancer therapy. DNA methyltransferase inhibitors, such as azacitidine, and histone deacetylase inhibitors, such as vorinostat, have been used in combination with chemotherapy to treat breast cancer. miRNA regulators, such as miRNA mimics and antagomiRs, can alter the expression of specific genes involved in cancer development. miRNA mimics, such as miR-34, have been used to inhibit tumor growth, while antagomiRs, such as anti-miR-10b, have been used to inhibit metastasis. The development of epi-drugs that target specific epigenetic changes may lead to more effective monotherapy options in the future.
Editor: Switzerland: MDPI AG
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA

Szczepanek, Joanna ; Skorupa, Monika ; Jarkiewicz-Tretyn, Joanna ; Cybulski, Cezary ; Tretyn, Andrzej

Switzerland: MDPI AG

Buscando em bases de dados remotas. Favor aguardar.